

# Patrizia Nanni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/152536/publications.pdf>

Version: 2024-02-01

100  
papers

4,850  
citations

87723

38  
h-index

98622

67  
g-index

101  
all docs

101  
docs citations

101  
times ranked

5797  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142.	0.4	326
2	2011: the immune hallmarks of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 319-326.	2.0	316
3	Vaccines for tumour prevention. <i>Nature Reviews Cancer</i> , 2006, 6, 204-216.	12.8	312
4	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596.	4.2	291
5	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206.	4.2	218
6	TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. <i>Clinical and Experimental Metastasis</i> , 1983, 1, 373-380.	1.7	203
7	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 1322-1330.	3.2	126
8	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. <i>Cancer Gene Therapy</i> , 2002, 9, 296-307.	2.2	101
9	CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine. <i>Journal of Immunology</i> , 2006, 176, 1750-1758.	0.4	96
10	Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. <i>Human Molecular Genetics</i> , 2014, 23, 1453-1466.	1.4	96
11	Molecular and cellular biology of rhabdomyosarcoma. <i>Future Oncology</i> , 2009, 5, 1449-1475.	1.1	91
12	A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene <i>MTND1</i> , an <i>Oncojanus</i> Function. <i>Cancer Research</i> , 2011, 71, 6220-6229.	0.4	90
13	Inhibition of tumor growth and enhancement of metastasis after transfection of the $\beta$ -interferon gene. <i>International Journal of Cancer</i> , 1993, 55, 320-329.	2.3	89
14	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- $\beta$ and B Cell Dependent. <i>Journal of Immunology</i> , 2004, 173, 2288-2296.	0.4	88
15	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. <i>Cancer Research</i> , 2004, 64, 4001-4009.	0.4	87
16	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. <i>Cancer Research</i> , 2004, 64, 1730-1736.	0.4	83
17	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9039-9044.	3.3	83
18	Virus-like particle display of HER2 induces potent anti-cancer responses. <i>Oncolmmunology</i> , 2018, 7, e1408749.	2.1	82

#	ARTICLE	IF	CITATIONS
19	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. <i>Cancer Research</i> , 2010, 70, 7755-7763.	0.4	78
20	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2 <sup>-/-</sup> ;Il2rg <sup>-/-</sup> Mice and Treatment with PI3K Inhibitor. <i>PLoS ONE</i> , 2012, 7, e39626.	1.1	78
21	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 186-194.	2.3	75
22	The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit. <i>American Journal of Pathology</i> , 2000, 157, 2123-2131.	1.9	73
23	c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. <i>Journal of Clinical Oncology</i> , 2003, 21, 1952-1960.	0.8	71
24	Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing's sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 91-96.	1.3	69
25	Rethinking herpes simplex virus: the way to oncolytic agents. <i>Reviews in Medical Virology</i> , 2011, 21, 213-226.	3.9	63
26	Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. <i>Cancer Research</i> , 2014, 74, 6248-6259.	0.4	63
27	Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. <i>Oncotarget</i> , 2015, 6, 34774-34787.	0.8	62
28	CD99 Acts as an Oncosuppressor in Osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006, 17, 1910-1921.	0.9	60
29	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937-941.		58
30	Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response. <i>International Journal of Cancer</i> , 2000, 87, 574-581.	2.3	56
31	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. <i>Cancer Research</i> , 2003, 63, 2728-32.	0.4	53
32	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. <i>Scientific Reports</i> , 2019, 9, 12174.	1.6	52
33	A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. <i>PLoS Pathogens</i> , 2018, 14, e1007209.	2.1	51
34	Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. <i>International Journal of Cancer</i> , 2006, 119, 1039-1046.	2.3	49
35	Antimetastatic Activity of a Preventive Cancer Vaccine. <i>Cancer Research</i> , 2007, 67, 11037-11044.	0.4	47
36	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. <i>Gene</i> , 2001, 274, 139-149.	1.0	46

#	ARTICLE	IF	CITATIONS
37	Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics, 2010, 11, S13.	1.2	44
38	Cancer immunoprevention. Future Oncology, 2005, 1, 57-66.	1.1	43
39	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. American Journal of Pathology, 2005, 166, 1205-1216.	1.9	43
40	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. Current Drug Targets, 2011, 12, 1957-1973.	1.0	39
41	The Promise of Preventive Cancer Vaccines. Vaccines, 2015, 3, 467-489.	2.1	38
42	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. PLoS Pathogens, 2013, 9, e1003155.	2.1	36
43	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	2.6	35
44	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	1.9	33
45	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. Journal of Cellular Physiology, 2019, 234, 1768-1779.	2.0	31
46	Interferon-mediated enhancement of metastasis. Are MHC antigens involved?. Clinical and Experimental Metastasis, 1987, 5, 277-287.	1.7	29
47	HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma Cells. Journal of Immunotherapy, 2002, 25, 314-323.	1.2	29
48	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. International Journal of Cancer, 2003, 105, 384-389.	2.3	28
49	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Research, 2014, 16, R10.	2.2	27
50	High metastatic efficiency of human sarcoma cells in Rag2 <sup>fl3c</sup> double knockout mice provides a powerful test system for antimetastatic targeted therapy. European Journal of Cancer, 2010, 46, 659-668.	1.3	26
51	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	1.2	22
52	High-metastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. Clinical and Experimental Metastasis, 1984, 2, 251-259.	1.7	20
53	Concomitant Amplification and Expression of PAX7-FKHR and MYCN in a Human Rhabdomyosarcoma Cell Line Carrying a Cryptic t(1;13)(p36;q14). Cancer Genetics and Cytogenetics, 2000, 121, 139-145.	1.0	20
54	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Molecular Cancer Therapeutics, 2009, 8, 754-761.	1.9	20

#	ARTICLE	IF	CITATIONS
55	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014, 15, S1.	1.2	20
56	Immunological Prevention of a Multigene Cancer Syndrome. <i>Cancer Research</i> , 2004, 64, 8428-8434.	0.4	19
57	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017, 8, 54444-54458.	0.8	19
58	Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma. , 1997, 71, 732-736.		17
59	Apc10.1: AnApcMin/+ intestinal cell line with retention of heterozygosity. <i>International Journal of Cancer</i> , 2004, 109, 200-206.	2.3	17
60	IFN- $\gamma$ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021, 13, 309.	1.7	17
61	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 1281-1286.	0.9	16
62	H-2Kb ANDH-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. <i>International Journal of Cancer</i> , 1994, 59, 269-274.	2.3	16
63	Immunological prevention of spontaneous tumors: a new prospect?. <i>Immunology Letters</i> , 2002, 80, 75-79.	1.1	16
64	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. <i>Journal of Translational Medicine</i> , 2014, 12, 122.	1.8	15
65	Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. <i>Cancers</i> , 2019, 11, 1889.	1.7	15
66	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 599-610.	2.0	14
67	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021, 10, 77.	2.1	14
68	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by $\text{I}\beta$ -interferon transfectants through host lymphocytes. <i>International Journal of Cancer</i> , 1995, 61, 425-430.	2.3	12
69	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. <i>Oncotarget</i> , 2014, 5, 108-119.	0.8	12
70	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	2.0	11
71	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015, 17, 70.	2.2	11
72	Karyotypic characterization of a new human embryonal rhabdomyosarcoma cell line. <i>Cancer Genetics and Cytogenetics</i> , 1991, 54, 83-89.	1.0	10

#	ARTICLE	IF	CITATIONS
73	Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 123-128.	1.7	10
74	Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: Lack of autocrine growth modulation. , 1998, 78, 441-445.		10
75	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER2/neu oncogene-driven animal model system. <i>Proteomics</i> , 2010, 10, 3835-3853.	1.3	10
76	Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. <i>Oncotarget</i> , 2014, 5, 11924-11938.	0.8	10
77	Cancer immunoprevention: from mice to early clinical trials. <i>BMC Immunology</i> , 2018, 19, 16.	0.9	9
78	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. <i>Pathology and Oncology Research</i> , 2007, 13, 336-339.	0.9	8
79	The prospects for cancer gene therapy. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1025-1032.	1.1	7
80	Preclinical HER-2 Vaccines: From Rodent to Human HER-2. <i>Frontiers in Oncology</i> , 2013, 3, 151.	1.3	7
81	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. <i>Cancers</i> , 2019, 11, 517.	1.7	7
82	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. <i>BMC Cancer</i> , 2019, 19, 126.	1.1	7
83	Immunoprevention of colorectal cancer: a future possibility?. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 1001-1014.	1.0	6
84	Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. <i>Scientific Reports</i> , 2021, 11, 1563.	1.6	6
85	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. <i>International Journal of Cancer</i> , 2007, 121, 88-94.	2.3	5
86	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. <i>Vaccine</i> , 2011, 29, 4690-4697.	1.7	4
87	The Molecular Basis of Herpesviruses as Oncolytic Agents. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1795-1803.	0.9	4
88	Heterogeneity and Clonal Interactions in the TS/A Murine Mammary Adenocarcinoma. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 5-14.	0.8	4
89	Immunoprevention and Immunotherapy of Mammary Carcinoma. <i>Breast Journal</i> , 2010, 16, S39-S41.	0.4	3
90	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2018, 7, e1465164.	2.1	3

#	ARTICLE	IF	CITATIONS
91	Interferon-Mediated Modulation of Metastasis and MHC Antigens. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 129-139.	0.8	3
92	Dexamethasone modulation of in vitro growth pattern and of lung colonization ability in clones of a metastatic BALB/c mammary carcinoma cell line. <i>Clinical and Experimental Metastasis</i> , 1986, 4, 13-23.	1.7	2
93	Modulation by Ifn-Gamma of the Metastatic Ability of Murine, Human, and H-2-Transfected Tumor Cells. <i>Tumori</i> , 1989, 75, 383-388.	0.6	2
94	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. <i>European Journal of Cancer</i> , 2006, 42, 680-687.	1.3	2
95	HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. <i>Cells</i> , 2021, 10, 1808.	1.8	2
96	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009, 27, 2065-2069.	1.7	1
97	<i>Immunoprevention.</i> , 2017, , 2223-2228.		1
98	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1
99	<i>Immunoprevention.</i> , 2011, , 1827-1830.		0
100	<i>Immunoprevention.</i> , 2014, , 1-6.		0